[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023007064A - Metodos para tratar la diabetes. - Google Patents

Metodos para tratar la diabetes.

Info

Publication number
MX2023007064A
MX2023007064A MX2023007064A MX2023007064A MX2023007064A MX 2023007064 A MX2023007064 A MX 2023007064A MX 2023007064 A MX2023007064 A MX 2023007064A MX 2023007064 A MX2023007064 A MX 2023007064A MX 2023007064 A MX2023007064 A MX 2023007064A
Authority
MX
Mexico
Prior art keywords
methods
treating diabetes
weekly
doses
dosing
Prior art date
Application number
MX2023007064A
Other languages
English (en)
Inventor
Juliana M Bue-Valleskey
Molly Corbett Carr
Annette Meeok Chang
A/K/A/ Jenny Y Chien Yueh - Ling Chien
Emmanuel Chigutsa
Parag Garhyan
Axel Richard Karl - August Haupt
Liza L Ilag
Michelle Lynne Katz
Christof Matthias Kazda
Karen Brenda Schneck
Cheng Cai Tang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2023007064A publication Critical patent/MX2023007064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En el presente documento se describen dosis y regímenes de dosificación que comprenden, determinan y administran dosis de agonistas del receptor de insulina de acción prolongada adecuadas para la dosificación una vez a la semana, como Insulina Basal Fc Semanal (BIF).
MX2023007064A 2020-12-14 2021-12-14 Metodos para tratar la diabetes. MX2023007064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125165P 2020-12-14 2020-12-14
PCT/US2021/063231 WO2022132709A1 (en) 2020-12-14 2021-12-14 Methods of treating diabetes

Publications (1)

Publication Number Publication Date
MX2023007064A true MX2023007064A (es) 2023-07-31

Family

ID=79287778

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023007064A MX2023007064A (es) 2020-12-14 2021-12-14 Metodos para tratar la diabetes.
MX2023007062A MX2023007062A (es) 2020-12-14 2021-12-14 Metodos de tratamiento de la diabetes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007062A MX2023007062A (es) 2020-12-14 2021-12-14 Metodos de tratamiento de la diabetes.

Country Status (11)

Country Link
US (2) US20240050532A1 (es)
EP (2) EP4259186A1 (es)
JP (2) JP2023554358A (es)
KR (2) KR20230118648A (es)
CN (2) CN116710119A (es)
AU (2) AU2021400816A1 (es)
CA (2) CA3199645A1 (es)
IL (2) IL303631A (es)
MX (2) MX2023007064A (es)
TW (2) TW202237174A (es)
WO (2) WO2022132712A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059480A2 (en) * 2022-09-12 2024-03-21 Eli Lilly And Company A gip/glp1 for use in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110026C2 (uk) 2010-03-01 2015-11-10 Пристрій для автоматичного виконання ін'єкції з механізмом затримки, який включає в себе пересувальний елемент подвійного призначення
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
WO2016001185A1 (en) 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
HUE058005T2 (hu) * 2018-06-29 2022-06-28 Akston Biosciences Corp Ultra hosszan ható inzulin Fc fehérjék, és alkalmazási eljárások
US20210393745A1 (en) * 2018-10-10 2021-12-23 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use

Also Published As

Publication number Publication date
IL303630A (en) 2023-08-01
CA3199645A1 (en) 2022-06-23
US20240050532A1 (en) 2024-02-15
US20240082363A1 (en) 2024-03-14
CN116710119A (zh) 2023-09-05
EP4259185A1 (en) 2023-10-18
JP2023554358A (ja) 2023-12-27
EP4259186A1 (en) 2023-10-18
JP2024502720A (ja) 2024-01-23
WO2022132712A1 (en) 2022-06-23
WO2022132709A1 (en) 2022-06-23
CA3202345A1 (en) 2022-06-23
MX2023007062A (es) 2023-06-23
IL303631A (en) 2023-08-01
KR20230118648A (ko) 2023-08-11
TW202237175A (zh) 2022-10-01
AU2021400816A1 (en) 2023-06-22
AU2021401635A9 (en) 2024-06-20
CN116723852A (zh) 2023-09-08
TW202237174A (zh) 2022-10-01
KR20230118936A (ko) 2023-08-14
AU2021401635A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
MX2023007064A (es) Metodos para tratar la diabetes.
Vennin et al. Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer.
Van Warmerdam et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
Augustin et al. Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy
Milewicz et al. Metformin--new treatment strategies for gynecologic neoplasms
Tefferi Ruxolitinib targets DCs: for better or worse?
Ban et al. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer-single institution experience.
Richter et al. The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma.
Pavlin et al. Optimal propofol-alfentanil combinations for supplementing nitrous oxide for outpatient surgery.
Li et al. Summary and expectation of the role of GnRHa in the treatment of breast cancer
Liu et al. Effect of psoralen on the stability after orthodontic tooth movement in rats
Arribas Del Amo et al. Direct-to-implant breast reconstruction after neoadjuvant chemotherapy: A safe option?
Legha et al. Phase I study of hycanthone.
Bishop Does it matter how remission is achieved in acute leukemia?
Chu et al. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Di Raimondo et al. Management of multiple myeloma
Kagawa et al. Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer
Ogura Progress in therapeutic strategy for malignant lymphoma
Latorzeff et al. Treatment of trigeminal neuralgia with radiosurgery
Forbes How to treat a difficult-to-anesthetize patient. Twelve alternatives to the traditional inferior alveolar nerve block.
Fabi et al. LHRH analogs: current role in early and advanced breast cancer treatment of premenopausal patients.
Nagashima et al. Effect of pegfilgrastim primary prophylactic administration on relative dose intensity (RDI) in postoperative adjuvant chemotherapy (TC therapy) for breast cancer-a single-center, retrospective study
Zagorulko et al. The efficacy of therapeutic nerve blocks in patients with cervicogenic headache
Liu et al. Clinical efficacy of sorafenib combined with low dose cytarabine for treating patients with FLT3+ relapsed and refractory acute myeloid leukemia